Assess whether pediatric studies are necessary or waivable (bd9944)

SITUATION The working file is disproportionate reporting signal workbook after a boxed-warning proposal from the review division. Clinical-development physician in a company with a CMC site change mid-review has to name Pediatric studies are necessary or Waivable for this Pharma & Life Sciences FDA Response and Labeling file.

DECISION Clinical-development physician in a company with a CMC site change mid-review must choose Pediatric studies are necessary / Waivable using disproportionate reporting signal workbook after a boxed-warning proposal from the review division.

HYPOTHESES TO TEST 1. Clinical-development physician can defend Pediatric studies are necessary from disproportionate reporting signal workbook after a boxed-warning proposal from the review division in a Pharma & Life Sciences challenge. 2. Clinical-development physician cannot defend Pediatric studies are necessary from disproportionate reporting signal workbook; Waivable is what the extract actually supports after a boxed-warning proposal from the review division. 3. A boxed-warning proposal from the review division never reached the population in disproportionate reporting signal workbook — reopen intake, do not close pediatric studies are necessary. 4. Two facts in disproportionate reporting signal workbook after a boxed-warning proposal from the review division conflict for clinical-development physician; hold this FDA Response and Labeling file.

ANALYSIS REQUIRED 1. Test a protocol deviation versus a safety signal versus a filing gap on pediatric studies are necessary. 2. Check whether disproportionate reporting signal workbook supports the labeled claim clinical-development physician would keep. 3. Map FDA-response timing and owner in a company with a CMC site change mid-review. 4. For this Pharma & Life Sciences FDA Response and Labeling file, read disproportionate reporting signal workbook against a boxed-warning proposal from the review division and write the one fact that would move pediatric studies are necessary for clinical-development physician.

RECOMMENDATION Choose Pediatric studies are necessary / Waivable on this Pharma & Life Sciences / FDA Response and Labeling packet (disproportionate reporting signal workbook after a boxed-warning proposal from the review division). The follow-on FDA Response and Labeling action is what clinical-development physician does next: implement the option, assign an owner, and log the missing fact.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on pediatric studies are necessary, then the evidence in disproportionate reporting signal workbook, then the action for clinical-development physician - Hypothesis scorecard against disproportionate reporting signal workbook: supported / rejected / untestable - Regulatory or exam hook FDA Response and Labeling would cite - FDA Response and Labeling finding in disproportionate reporting signal workbook that a second reviewer can re-perform